Skip to main content

Table 1 Baseline characteristics of patients with newly developed atrial fibrillation in the Intego database (2002–2011)a

From: Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study

 

Atrial fibrillation

Control

P value*

(n = 1830)

(n = 6622)

Age (years), mean ± SD

77.5 ± 7.3

77.0 ± 7.2

0.006

Men, n (%)

900 (49.2)

3253 (49.1)

0.97

Cardiovascular medication before the diagnosis of atrial fibrillation, n (%)

1005 (54.9)

2523 (38.1)

<0.001

 Diuretic, n (%)

495 (27.0)

1198 (18.1)

<0.001

 β blocker, n (%)

603 (33.0)

1357 (20.5)

<0.001

 Calcium channel blocker, n (%)

303 (16.6)

674 (10.2)

<0.001

 ACE-inhibitor, n (%)

340 (18.6)

756 (11.4)

<0.001

 ARB, n (%)

172 (9.4)

440 (6.6)

<0.001

Comorbidity

   

 Charlson Comorbidity Index, mean ± SD

5 ± 2

4 ± 2

<0.001

  Myocardial infarction, n (%)

235 (12.8)

513 (7.7)

<0.001

  Heart failure, n (%)

214 (11.7)

260 (3.9)

<0.001

  Peripheral vascular disease, n (%)

149 (8.1)

400 (6.0)

0.001

  Cerebrovascular event, n (%)

259 (14.2)

633 (9.6)

<0.001

  Dementia, n (%)

62 (3.4)

242 (3.7)

0.59

  Chronic pulmonary disease, n (%)

47 (2.6)

175 (2.6)

0.86

  History of peptic ulcers, n (%)

150 (8.2)

472 (7.1)

0.12

  Liver disease, n (%)

57 (3.1)

184 (2.8)

0.44

  Diabetes, n (%)

319 (17.4)

884 (13.3)

<0.001

  Hemiplegia, n (%)

30 (1.6)

71 (1.1)

0.048

  Renal disease, n (%)

208 (11.9)

480 (8.1)

<0.001

  History of tumours, n (%)

237 (13.0)

922 (13.9)

0.28

  Leukaemia, n (%)

5 (0.3)

24 (0.4)

0.56

  Lymphoma, n (%)

7 (0.4)

33 (0.5)

0.52

 Hypertension, n (%)

780 (42.6)

2213 (33.4)

<0.001

 Valve disease, n (%)

181 (9.9)

235 (3.5)

<0.001

  1. a, the date of diagnosis of atrial fibrillation served as the baseline date for the case and its matched controls; *, independent samples t-test or Chi2 test
  2. SD standard deviation, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker